DICE Therapeutics, Inc. (DICE) [Rocket]

In millions, except per share items	Dec-31-22	Dec-05-22	Dec-31-21	Dec-05-21	Dec-31-20	Dec-31-19
	10-K	8-K	10-K	8-K	10-K	S-1/A
Revenues	0.0	62.6	1.1	36.5	0.9	15.7
Revenue growth	-100.0%	71.4%	30.4%		-94.5%
Cost of goods sold	0.0	88.2	0.0	48.7	0.0	25.7
Gross profit	0.0	-25.7	1.1	-12.2	0.9	-9.9
Gross margin		-41.0%	100.0%	-33.5%	100.0%	-63.3%
Selling, general and administrative [+]	88.2	25.7	48.7	12.2	5.0	3.6
General and administrative		25.7		12.2	5.0	3.6
Research and development					19.6
Other operating expenses	-88.2	36.9	0.0	23.2
EBITDA [+]					-23.0	-12.8
EBITDA growth	-100.0%	85.3%	106.9%		79.3%
EBITDA margin		-141.0%	-4234.8%	-130.4%	-2667.9%	-81.7%
Depreciation and amortization					0.7	0.7
EBIT [+]	0.0	-88.2	-47.6	-47.6	-23.7	-13.5
EBIT growth	-100.0%	85.3%	100.8%		75.1%
EBIT margin		-141.0%	-4234.8%	-130.4%	-2748.7%	-86.2%
Interest expense					0.0	0.0
Interest expense					0.0	0.0
Other income (expense), net [+]	-83.9	4.3	-1.3	-1.4	0.0	0.6
Gain (loss) on debt retirement		-0.2
Change in fair value of warrants			1.3		-0.1
Pre-tax income	-83.9	-83.9	-49.0	-49.0	-23.7	-12.9
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-83.9	-83.9	-49.0	-49.0	-23.7	-12.9
Net margin		-134.1%	-4351.9%	-134.1%	-2750.8%	-82.3%

Basic EPS [+]	($2.13)	($2.13)	($3.95)	($3.95)	($10.56)	($5.75)
Growth	-46.1%	-46.1%	-62.6%		83.5%
Diluted EPS [+]	($2.13)	($2.13)	($3.95)	($3.95)	($10.56)	($5.75)
Growth	-46.1%	-46.1%	-62.6%		83.5%

Shares outstanding (basic) [+]	39.4	39.4	12.4	12.4	2.2	2.2
Growth	218.2%	218.2%	450.7%		0.0%
Shares outstanding (diluted) [+]	39.4	39.4	12.4	12.4	2.2	2.2
Growth	218.2%	218.2%	450.7%		0.0%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.